GLP-1 & The Heart: Cardiovascular Benefits, Not Risks
GLP-1 medications actually reduce cardiovascular events in high-risk patients. Here\'s the SELECT trial, the heart failure data, and what it means for your heart.
The SELECT Trial: 20% Reduction in Cardiovascular Events
SELECT was a large randomized trial (n=17,604) of Wegovy (semaglutide 2.4 mg) in adults with obesity and established cardiovascular disease. Over a median 39 months, Wegovy reduced major adverse cardiovascular events (MACE — heart attack, stroke, cardiovascular death) by 20% vs. placebo.
This led to the 2024 FDA expansion of Wegovy\'s indication to include cardiovascular event reduction in adults with obesity + heart disease. It\'s the first weight-loss medication ever approved for cardiovascular benefit.
Tirzepatide and Heart Failure (SUMMIT Trial)
Tirzepatide (Zepbound) was studied in adults with heart failure with preserved ejection fraction (HFpEF) and obesity. The SUMMIT trial showed significant improvements in symptoms and exercise capacity, and specific HF approval is being pursued.
Why GLP-1s Help the Heart
- Weight loss itself reduces cardiac workload
- Improved blood sugar reduces cardiovascular damage
- Lower blood pressure (2-5 mmHg systolic in trials)
- Improved lipid profile (modest LDL reduction)
- Anti-inflammatory effects on blood vessels
- Direct effects on cardiac tissue (still being studied)
Modest Heart Rate Increase
GLP-1 medications cause a small (2-5 bpm) increase in resting heart rate. The clinical significance is unclear; cardiovascular outcome trials show net benefit despite this. People with severe arrhythmias should discuss with their cardiologist before starting.